{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:31:56Z","timestamp":1740173516201,"version":"3.37.3"},"reference-count":32,"publisher":"Endocrinology Research Centre","issue":"3","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>Multiple sclerosis (MS) is a severe chronic autoimmune demyelinating disease of the central nervous system, mediated by Th1\/Th17 lymphocytes as well as B lymphocytes, macrophages and other immune cells. Some patients with MS are treated with alemtuzumab, a monoclonal antibody against CD52+ cells, which belongs to the disease-modifying therapies (DMTs). The main effect of alemtuzumab is related to changes in immune recruitment. Alemtuzumab therapy can induce secondary autoimmunity against the background of immune rebalancing. The thyroid gland is generally involved in the autoimmune process. Graves\u2019 disease (GD) develops most often, followed by autoimmune thyroiditis.<\/jats:p><jats:p>We present a clinical case of a patient with GD developed after alemtuzumab therapy for MS. The patient was referred to a radiologist at the Department of Radionuclide Therapy of Endocrinology Research Centre for radioiodine therapy (RAIT) due to relapse of thyrotoxicosis after anti-thyroid drug therapy for GD. The goal of treatment was achieved in 2 months, thyroid hormone therapy was initiated, against the background of this, there was compensation of thyroid function.<\/jats:p>","DOI":"10.14341\/probl13238","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:21:00Z","timestamp":1688995260000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":1,"title":["Alemtuzumab-induced Graves\u2019 disease"],"prefix":"10.14341","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-0335","authenticated-orcid":true,"given":"M. S.","family":"Sheremeta","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6954-1126","authenticated-orcid":true,"given":"M. O.","family":"Korchagina","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8694-2474","authenticated-orcid":true,"given":"R. M.","family":"Guseinova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5037-0809","authenticated-orcid":true,"given":"T. E.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"I.M. Sechenov First Moscow State Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2478-8712","authenticated-orcid":true,"given":"K. S.","family":"Nizhegorodova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8538-5354","authenticated-orcid":true,"given":"N. Yu.","family":"Sviridenko","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7877","authenticated-orcid":true,"given":"G. A.","family":"Melnichenko","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"ref1","unstructured":"Rassejannyj skleroz i drugie demielinizirujushhie zabolevanija. Ed. by Gusev EI, Zavalishin IA, Bojko AN. Moscow: Miklosh; 2004. \u2014 540 p. (In Russ.)."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med. 2018;8(9):a028928. doi: https:\/\/doi.org\/10.1101\/cshperspect.a028928","DOI":"10.1101\/cshperspect.a028928"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Sawcer S. The complex genetics of multiple sclerosis: pitfalls and prospects. Brain. 2008;131(Pt12):3118-3131. doi: https:\/\/doi.org\/10.1093\/brain\/awn081","DOI":"10.1093\/brain\/awn081"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"\u2018t Hart BA, Hintzen RQ, Laman JD. Multiple sclerosis \u2014 a response-to-damage model. Trends Mol Med. 2009;15(6):235-244. doi: https:\/\/doi.org\/10.1016\/j.molmed.2009.04.001","DOI":"10.1016\/j.molmed.2009.04.001"},{"key":"ref5","unstructured":"Demina TL, Davydovskaja MV, Hachanova NV, i dr. Rassejannyj skleroz: patogenez, diagnostika, differencial\u2019nyj diagnoz i lechenie. Consilium medicum. 2008;(1):61-68. (In Russ.)."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16(6):s53-s59. doi: https:\/\/doi.org\/10.7861\/clinmedicine.16-6-s53","DOI":"10.7861\/clinmedicine.16-6-s53"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ghezzi A. European and American Guidelines for Multiple Sclerosis Treatment. Neurol Ther. 2018;7(2):189-194. doi: https:\/\/doi.org\/10.1007\/s40120-018-0112-1","DOI":"10.1007\/s40120-018-0112-1"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis [published correction appears in Eur J Neurol. 2018;25(3):605]. Eur J Neurol. 2018;25(2):215-237. doi: https:\/\/doi.org\/10.1111\/ene.13536","DOI":"10.1111\/ene.13536"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: Mechanism of action and Beyond. Int J Mol Sci. 2015;16(7):16414-16439. doi: https:\/\/doi.org\/10.3390\/ijms160716414","DOI":"10.3390\/ijms160716414"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86(2):208-215. doi: https:\/\/doi.org\/10.1136\/jnnp-2014-307721","DOI":"10.1136\/jnnp-2014-307721"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Pariani N, Willis M, Muller I, et al. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab. 2018;103(8):3010-3018. doi: https:\/\/doi.org\/10.1210\/jc.2018-00359","DOI":"10.1210\/jc.2018-00359"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Havrdova E, Arnold DL, Cohen JA, et al. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy [published correction appears in Neurology. 2018;90(16):755]. Neurology. 2017;89(11):1107-1116. doi: https:\/\/doi.org\/10.1212\/WNL.0000000000004313","DOI":"10.1212\/WNL.0000000000004313"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017;89(11):1117-1126. doi: https:\/\/doi.org\/10.1212\/WNL.0000000000004354","DOI":"10.1212\/WNL.0000000000004354"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Khachanova NV, Bakhtiyarova KZ, Boyko AN, et al. Updated recommendations of the council of experts on the use and safety of alemtuzumab (Lemtrada). Zhurnal nevrologii i psikhiatrii im SS Korsakova. 2020;120(3):82-91. (In Russ.). doi: https:\/\/doi.org\/10.17116\/jnevro202012003182","DOI":"10.17116\/jnevro202012003182"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Hemmer B, Archelos JJ, Hartung H-P. New concepts in the immunopathogenesis of multiple sclerosis. Nat Rev Neurosci. 2002;3(4):291-301. doi: https:\/\/doi.org\/10.1038\/nrn784","DOI":"10.1038\/nrn784"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci. 2003;24(3):131-138. doi: https:\/\/doi.org\/10.1016\/S0165-6147(03)00028-2","DOI":"10.1016\/S0165-6147(03)00028-2"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol. 2001;2(9):762-764. doi: https:\/\/doi.org\/10.1038\/ni0901-762","DOI":"10.1038\/ni0901-762"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain. 2003;126(Pt2):433-437. doi: https:\/\/doi.org\/10.1093\/brain\/awg038","DOI":"10.1093\/brain\/awg038"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Trapp BD, Ransohoff RM, Fisher E, Rudick RA. Neurodegeneration in multiple sclerosis: Relationship to neurological disability. The Neuroscientist. 1999;5(1):48-57. doi: https:\/\/doi.org\/10.1177\/107385849900500107","DOI":"10.1177\/107385849900500107"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi: https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99(1):80-89. doi: https:\/\/doi.org\/10.1210\/jc.2013-2201","DOI":"10.1210\/jc.2013-2201"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Scappaticcio L, Castellana M, Virili C, et al. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J Endocrinol Invest. 2020;43(2):219-229. doi: https:\/\/doi.org\/10.1007\/s40618-019-01105-7","DOI":"10.1007\/s40618-019-01105-7"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 2017;74(8):961-969. doi: https:\/\/doi.org\/10.1001\/jamaneurol.2017.0676","DOI":"10.1001\/jamaneurol.2017.0676"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Rydzewska M, Jaromin M, Pasierowska IE, et al. Role of the T and B lymphocytes in pathogenesis of autoimmune thyroid diseases. Thyroid Res. 2018;11(1):2. doi: https:\/\/doi.org\/10.1186\/s13044-018-0046-9","DOI":"10.1186\/s13044-018-0046-9"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Antonelli A, Fallahi P, Elia G, et al. Graves\u2019 disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101388. doi: https:\/\/doi.org\/10.1016\/j.beem.2020.101388","DOI":"10.1016\/j.beem.2020.101388"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Gallo D, Piantanida E, Gallazzi M, et al. Immunological drivers in Graves\u2019 Disease: NK cells as a Master Switcher. Front Endocrinol (Lausanne). 2020;11(1):2. doi: https:\/\/doi.org\/10.3389\/fendo.2020.00406","DOI":"10.3389\/fendo.2020.00406"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Scappaticcio L, Castellana M, Virili C, et al. Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis. J Endocrinol Invest. 2020;43(2):219-229. doi: https:\/\/doi.org\/10.1007\/s40618-019-01105-7","DOI":"10.1007\/s40618-019-01105-7"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Gallo D, Piantanida E, Gallazzi M, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801. doi: https:\/\/doi.org\/10.1056\/NEJMoa0802670","DOI":"10.1056\/NEJMoa0802670"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Cossburn M, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573-579. doi: https:\/\/doi.org\/10.1212\/WNL.0b013e318228bec5","DOI":"10.1212\/WNL.0b013e318228bec5"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Muller I, Moran C, Lecumberri B, et al. 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy. Eur Thyroid J. 2019;8(4):173-185. doi: https:\/\/doi.org\/10.1159\/000500881","DOI":"10.1159\/000500881"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Decallonne B, Bartholom\u00e9 E, Delvaux V, et al. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management. Acta Neurol Belg. 2018;118(2):153-159. doi: https:\/\/doi.org\/10.1007\/s13760-018-0883-2","DOI":"10.1007\/s13760-018-0883-2"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Devonshire V, Phillips R, Wass H, et al. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol. 2018;265(11):2494-2505. doi: https:\/\/doi.org\/10.1007\/s00415-018-8822-y","DOI":"10.1007\/s00415-018-8822-y"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13238\/10486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:34:10Z","timestamp":1688996050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,7,8]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13238","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2023,6,30]]}}}